jcm-logo

Journal Browser

Journal Browser

Advances in the Colorectal Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "General Surgery".

Deadline for manuscript submissions: closed (25 December 2024) | Viewed by 973

Special Issue Editor


E-Mail Website
Guest Editor
Washington University School of Medicine, St. Louis, MO, USA
Interests: gastrointestinal malignancies

Special Issue Information

Dear Colleagues,

Colorectal cancer is the second leading cause of death from cancer in the United States. In 2023, 1,535,020 new cases of colorectal cancer have been diagnosed with over 52,550 deaths. Although the overall mortality is declining, the mortality has increased from 0.5 to 3% annually in the younger age group (under 55 years of age). There has been an increase in left-sided versus right-sided tumors. The use of immunotherapy regimens for mismatch repair-deficient colorectal cancer and use of targeted therapy, like the combination of trastuzumab and tucatinb for HER2-positive colorectal cancer, has definitely made an impact on outcomes for patients with metastatic colorectal cancer. The use of genomic testing upfront to guide treatment decisions has been key in improving progression-free survival and overall survival for patients with colorectal cancer. In patients with colorectal cancer that have liver-only metastases, the varied liver-directed treatment options, like transarterial chemoembolization, transarterial radioembolization, radiofrequency ablation, liver transplant and use of hepatic artery infusion pump therapy, have accelerated the progress in the metastatic colorectal arena.

In this Special Issue, you are invited as an expert in the field to share your insight and submit a manuscript on the novel research and treatment strategies that have advanced the survival of patients with colorectal cancer.

Dr. Olivia Aranha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • progress
  • treatment
  • liver-directed therapy
  • radiation
  • immunotherapy
  • mismatch repair deficient
  • microsatellite instability
  • genomics
  • peritoneal carcinomatosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 741 KiB  
Brief Report
Effectiveness of Subcutaneous Negative-Suction Drain on Surgical Site Infection After Ileostomy Reversal: A Propensity Score Matching Analysis
by Ju Myung Song, Ji Hoon Kim, Moon Jin Kim, Chae Dong Lim and Yoon Suk Lee
J. Clin. Med. 2025, 14(1), 236; https://doi.org/10.3390/jcm14010236 - 3 Jan 2025
Viewed by 595
Abstract
Background/Objective: Surgical site infection (SSI) is a leading common condition after ileostomy reversal (IR). However, evidence is unclear that subcutaneous negative-suction drainage (SND) reduces the incidence of SSI. This study aimed to investigate whether SND effectively reduced the incidence of SSI. Methods: We [...] Read more.
Background/Objective: Surgical site infection (SSI) is a leading common condition after ileostomy reversal (IR). However, evidence is unclear that subcutaneous negative-suction drainage (SND) reduces the incidence of SSI. This study aimed to investigate whether SND effectively reduced the incidence of SSI. Methods: We retrospectively analyzed the records of 531 patients who underwent IR at Incheon St. Mary’s Hospital between June 2005 and December 2020. SND was classified into two groups based on its presence or absence. The estimated risk of SSI was calculated using the surgical risk calculator of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP). After 1:1 propensity score matching (PSM) using the estimated risk of SSI, we analyzed the two group’s postoperative outcomes, including SSI rates. Results: After PSM, there was no difference in demographics between the two groups; however, the reversal interval was longer in the SND group than in the no SND group (193.3 ± 151.6 vs. 151.5 ± 141.0 days, p = 0.005). The incidence of SSI was lower in the SND group than in the no SND group (5.2% vs. 13.0%, p = 0.013). Conclusions: SND insertion can reduce the incidence of SSI during IR. Therefore, SND insertion should be considered as a basic technique for reducing SSI after IR. Full article
(This article belongs to the Special Issue Advances in the Colorectal Cancer)
Show Figures

Figure 1

Back to TopTop